Dr. Reddy'S Labs Peer Comparison

NSE: DRREDDY | BSE: 500124

₹1,370.00

₹-3.00 (-0.22%)

As on 08-Nov-2026IST

Market cap

₹1,14,349 Cr

Revenue (TTM)

₹33,097 Cr

P/E Ratio

40.8

P/B Ratio

2.9

Div. Yield

0.6 %

Edit

	Dr. Reddy'S Labs	Zydus Lifesciences	Mankind Pharma	Aurobindo Pharma	Lupin
Market cap (₹ Cr)	1,14,349	1,19,700	1,06,446	1,03,913	91,230
Revenue (₹ Cr)	33,097	30,378	15,379	36,913	30,746
Net Profit (₹ Cr)	2,759.70	4,159.00	2,249.69	3,993.05	5,221.47
Net Margin (%)	8.03	13.20	14.32	10.61	16.70
RoE (%)	7.30	16.61	13.86	10.51	24.24
Price to Earnings	40.84	28.64	47.46	26.04	17.52
Price-To-Book	2.95	4.30	6.05	2.64	3.79

Income Statement (₹ Cr)

	Dr. Reddy'S Labs	Zydus Lifesciences	Mankind Pharma	Aurobindo Pharma	Lupin
Operating Revenue	33,097.40	30,378.10	15,378.58	36,912.88	30,746.33
Total Income	34,352.50	31,504.60	15,705.47	37,650.01	31,258.85
Total Expenditure	28,236.90	22,828.30	11,301.83	29,349.95	21,504.94
EBITDA	4,860.50	7,549.80	4,076.75	7,562.93	9,241.39
Depreciation	2,141.40	2,027.20	907.11	1,961.27	1,698.50
EBIT	2,719.10	5,522.60	3,169.64	5,601.66	7,542.89
Interest	450.40	595.90	513.87	394.85	450.49
Other Income	1,255.10	1,126.50	326.89	737.13	512.52
Exceptional Items	0.00	-499.30	-129.75	-105.51	-557.91
Profit before Tax	3,523.80	5,553.90	2,852.91	5,838.43	7,047.01
Provision for Tax	764.10	1,394.90	603.22	1,845.38	1,825.54
Profit after Tax	2,759.70	4,159.00	2,249.69	3,993.05	5,221.47

	Dr. Reddy'S Labs	Zydus Lifesciences	Mankind Pharma	Aurobindo Pharma	Lupin
Shareholder's Funds	38,807.00	27,817.30	17,582.22	39,399.90	24,050.46
Minority Interest	40.20	-101.90	-20.87	3.68	-15.31
Non-Current Liabilities	3,074.90	7,260.60	5,214.33	2,689.12	3,318.63
Current Liabilities	15,430.30	18,023.50	5,884.79	19,667.17	12,541.26
Total Liabilities	56,576.70	50,672.60	27,754.83	58,196.15	38,146.06

	Dr. Reddy'S Labs	Zydus Lifesciences	Mankind Pharma	Aurobindo Pharma	Lupin
Non-Current Assets	26,891.10	36,142.90	20,096.89	26,331.59	14,387.96
Current Assets	29,732.20	18,433.50	7,956.27	33,958.66	23,070.16
Total Assets	56,576.70	50,672.60	27,754.83	58,196.15	38,146.06
Total Debt*	7,734.10	11,769.50	6,021.78	7,676.20	5,910.20
Net Current Assets	14,301.90	410.00	2,071.48	14,291.49	10,528.90
Contingent Liabilities	336.14	989.90	924.77	1,358.37	1,094.02

	Dr. Reddy'S Labs	Zydus Lifesciences	Mankind Pharma	Aurobindo Pharma	Lupin
Cash From Operating Activities	5,673.70	2,116.60	3,121.29	5,526.37	7,334.50
Cash Flow from Investing Activities	-6,549.30	-8,296.10	-196.42	-3,458.61	-3,864.59
Cash from Financing Activities	829.00	5,806.90	-2,952.69	-1,269.15	-845.87
Net Cash Inflow / Outflow	-46.60	-372.60	-27.82	798.61	2,624.04

	Dr. Reddy'S Labs	Zydus Lifesciences	Mankind Pharma	Aurobindo Pharma	Lupin
ROCE (%)	13.75	21.39	13.24	12.76	28.86
ROE (%)	7.30	16.61	13.86	10.51	24.24
ROA (%)	4.93	8.11	7.79	6.99	14.23
EBIT Margin (%)	8.22	18.18	20.61	15.18	24.53
Net Margin (%)	8.03	13.20	14.32	10.61	16.70
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Dr. Reddy'S Labs	Zydus Lifesciences	Mankind Pharma	Aurobindo Pharma	Lupin
Revenue Growth (%)	-3.53	24.02	13.53	13.53	24.22
EBIT Growth (%)	-58.47	-16.48	31.59	13.09	38.02
Net Profit Growth (%)	-51.77	-16.41	27.79	15.82	20.10
EPS Growth (%)	-51.50	-10.25	34.22	19.29	30.16
Book Value Growth (%)	12.99	13.19	13.74	16.04	30.75

	Dr. Reddy'S Labs	Zydus Lifesciences	Mankind Pharma	Aurobindo Pharma	Lupin
Price / Earnings	40.81	26.37	45.32	25.69	16.18
Price / Book Value	2.95	4.30	6.05	2.64	3.79
Dividend Yield (%)	0.58	0.08	0.04	0.22	0.90
EV/EBITDA	23.67	16.46	27.09	13.35	9.51
Market Cap (₹ Cr)	1,04,763.81	87,643.18	82,801.75	75,689.14	1,05,737.27

	Dr. Reddy'S Labs	Zydus Lifesciences	Mankind Pharma	Aurobindo Pharma	Lupin
Debt to Equity	0.00	0.15	0.17	0.02	0.06
Short term debt to equity ratio	0.16	0.16	0.04	0.16	0.18
Current Ratio	1.93	1.02	1.35	1.73	1.84
Quick Ratio	1.40	0.64	0.95	1.06	1.32
Interest Coverage	8.82	10.32	6.55	15.79	16.64

	Dr. Reddy'S Labs	Zydus Lifesciences	Mankind Pharma	Aurobindo Pharma	Lupin
Debtors to sales (%)	30.64	14.42	14.17	20.44	21.65
Asset Turnover	0.59	0.59	0.53	0.65	0.84
Receivable days	103.79	33.55	39.93	33.71	51.23
Inventory Days	79.94	33.80	51.78	59.32	48.93
Payable days	84.78	149.82	111.46	148.20	205.75
Cash Conversion Cycle	98.95	-82.46	-19.75	-55.17	-105.59

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.